REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
01/12/2025
Voltar para busca
Dado oficial do USPTO
XELLERA THERAPUTICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Snapshot rápido
ST13
US500000088977235Classe
9, 10, 40, 42, 44
Pedido
88977235
Registro
6211225
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
31
Atualização mais recente
02/12/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
9, 10, 40, 42, 44
Data de depósito
27/05/2019
Data de registro
01/12/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
01/12/2020
Última transação
02/12/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
5
Tipo de titular
99
Localização do titular
HUNG HOM, KLN, HK
Examinador
KAPLAN,VALERIE ELIZABETH
Unidade examinadora
L70
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the wording "Xellera Theraputics" in a stylized font.
Titulares e representantes
Titulares
XELLERA THERAPEUTICS LIMITED
Representantes
Kevin O'Keefe
Classificação técnica
Classes Nice
Classe 9Classe 10Classe 40Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 9
bioreactor for cell culturing; Bioreactors for laboratory use; Research laboratory analyzers for measuringtesting and analyzing blood and other bodily fluids; Computer-controlled electronic apparatus for electrophysiological measurement and testing of cells
Classe 10
Apparatus for the regeneration of stem cells for medical purposes; Medical apparatus and instrument for diagnostic useapparatus for medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testingcytology and cell-based testing; Medical apparatus and instruments for treating cardiovascular disease; Medical apparatus for introducing pharmaceutical preparations into the human body; Medical diagnostic apparatus for testing blood antigens and antibodies
Classe 40
Biomanufacturing for othersmanufacturing of pharmaceuticals using biological organisms in the manufacturing process; Contract manufacturing in the field of biotechnology; Cryogenic preservation; Cryopreservation of human tissue; Custom manufacture of biopharmaceuticals by pharmaceutical compounders; Manufacture of pharmaceuticals to order and/or specification of others; Manufacturing services for others in the field of stem cells; Providing technical information in the field of pharmaceutical manufacturing
Classe 42
Biological research; Biomedical research services; Biotechnology research; Chemical research; Conducting clinical trials for others; Conducting early evaluations in the field of new pharmaceuticals; Development of pharmaceutical preparations and medicines; Drug discovery services; Industrial research in the field of regenerative and reparative therapies; Medical laboratory services; Medical research; Pharmaceutical drug development services; Pharmaceutical research services; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development in the pharmaceutical and biotechnology fields; Research and development of new products for others; Research and development of vaccines and medicines; Scientific research; Scientific research and development; Scientific research in the field of gene therapy; Stem cell research services; Technology research in the field of regenerative and reparative therapies
Classe 44
Blood bank services; Health care servicesregenerative and reparative therapies; Human tissue bank services; Medical care; Medical services; Medical services in the field of regenerative and reparative therapies; Medical testing for diagnostic or treatment purposes in the field of regenerative and reparative therapies; Organ and tissue bank services; Stem cell therapy services
Publicações
Histórico de despachos e eventos da marca no USPTO.
31 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/12/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/12/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/12/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
01/12/2020
CORV
REVIEW OF CORRESPONDENCE COMPLETE
29/10/2020
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
29/10/2020
IUCN
NOTICE OF ALLOWANCE CANCELLED
07/10/2020
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
07/10/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
23/06/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
28/04/2020
PUBO
PUBLISHED FOR OPPOSITION
28/04/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/04/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
25/03/2020
DPCC
DIVISIONAL PROCESSING COMPLETE
25/03/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
24/03/2020
ALIE
ASSIGNED TO LIE
27/02/2020
DRRR
DIVISIONAL REQUEST RECEIVED
23/02/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
23/02/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
23/02/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
23/02/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
23/02/2020
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
23/02/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
31/12/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
31/12/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
22/08/2019
GNRT
NON-FINAL ACTION E-MAILED
22/08/2019
CNRT
NON-FINAL ACTION WRITTEN
22/08/2019
DOCK
ASSIGNED TO EXAMINER
15/08/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/06/2019
NWAP
NEW APPLICATION ENTERED
30/05/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace XELLERA THERAPUTICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.